Linnea Chap

3.2k total citations · 1 hit paper
28 papers, 1.7k citations indexed

About

Linnea Chap is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Linnea Chap has authored 28 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Linnea Chap's work include Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Linnea Chap is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Linnea Chap collaborates with scholars based in United States, Spain and France. Linnea Chap's co-authors include Beth Overmoyer, Kathy D. Miller, Maura N. Dickler, Melody Cobleigh, Frankie A. Holmes, Amy P. Sing, Louis Fehrenbacher, P. Kelly Marcom, Virginia K. Langmuir and James D. Reimann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Linnea Chap

26 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

2005 1.0k citations Kathy D. Miller, Linnea Chap et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Linnea Chap United States	13	1.0k	662	417	367	207	28	1.7k
Blair Marshall United States	9	630 0.6×	795 1.2×	487 1.2×	514 1.4×	67 0.3×	10	1.7k
Cecilia Nisticò Italy	23	1.2k 1.1×	306 0.5×	555 1.3×	403 1.1×	71 0.3×	70	1.6k
Elena De Mattia Italy	25	963 0.9×	725 1.1×	279 0.7×	324 0.9×	239 1.2×	92	2.0k
Marlies H.G. Langenberg Netherlands	15	749 0.7×	604 0.9×	367 0.9×	417 1.1×	80 0.4×	34	1.3k
Reet Koomägi Germany	25	766 0.7×	1.3k 2.0×	675 1.6×	385 1.0×	161 0.8×	59	2.0k
Jackie Walling United States	16	1.0k 1.0×	671 1.0×	252 0.6×	878 2.4×	129 0.6×	45	1.9k
L. Austin Doyle United States	27	881 0.8×	1.1k 1.6×	398 1.0×	850 2.3×	116 0.6×	71	2.2k
Philippe Montcuquet France	16	581 0.6×	247 0.4×	248 0.6×	332 0.9×	71 0.3×	38	919
Nobuyuki Mizunuma Japan	23	1.5k 1.4×	506 0.8×	367 0.9×	530 1.4×	59 0.3×	133	2.0k
Carmelo Tibaldi Italy	20	1.5k 1.4×	604 0.9×	351 0.8×	991 2.7×	61 0.3×	73	2.1k

Countries citing papers authored by Linnea Chap

Since Specialization

Citations

This map shows the geographic impact of Linnea Chap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linnea Chap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linnea Chap more than expected).

Fields of papers citing papers by Linnea Chap

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linnea Chap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linnea Chap. The network helps show where Linnea Chap may publish in the future.

Co-authorship network of co-authors of Linnea Chap

This figure shows the co-authorship network connecting the top 25 collaborators of Linnea Chap. A scholar is included among the top collaborators of Linnea Chap based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linnea Chap. Linnea Chap is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

García-Sáenz, José Á., Gonzalo Spera, Marina Pollán, et al.. (2025). Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. International Journal of Cancer. 157(4). 709–721. 1 indexed citations

Bulat, Iurie, Philippe Aftimos, Patrick Neven, et al.. (2021). Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.. Journal of Clinical Oncology. 39(15_suppl). 1063–1063. 21 indexed citations

Rugo, Hope S., Giulia Bianchi, Stephen Chia, et al.. (2018). BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.. Journal of Clinical Oncology. 36(15_suppl). TPS1107–TPS1107. 9 indexed citations

Jhaveri, Komal, Kathy D. Miller, Lee S. Rosen, et al.. (2012). A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. Clinical Cancer Research. 18(18). 5090–5098. 49 indexed citations

Puzanov, Igor, John Sarantopoulos, Jeremy L. Gilbert, et al.. (2010). Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3018–3018. 4 indexed citations

Rosen, Lee S., et al.. (2010). Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review. The Oncologist. 15(3). 216–235. 37 indexed citations

Chap, Linnea. (2010). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Breast Diseases A Year Book Quarterly. 21(1). 78–79. 1 indexed citations

Herbst, Roy S., David S. Hong, Linnea Chap, et al.. (2009). Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 27(21). 3557–3565. 185 indexed citations

Eiermann, W., Tadeusz Pieńkowski, John Crown, et al.. (2009). BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.. Cancer Research. 69(2_Supplement). 77–77. 23 indexed citations

10.

Rosen, Lee S., David S. Hong, Linnea Chap, et al.. (2007). First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3522–3522. 9 indexed citations

11.

Chap, Linnea, et al.. (2006). The Revlon/UCLA Breast Center Practice Guidelines for the Treatment of Breast Disease.. PubMed. 2(1). 2–15.

12.

Slamon, DJ, Linnea Chap, Sophia K. Apple, et al.. (2005). Neoadjuvant docetaxel (T), carboplatin (C), with or without trastuzumab (H) for T3 and T4 breast cancer. Journal of Clinical Oncology. 23(16_suppl). 845–845. 1 indexed citations

13.

Bolwell, Brian J., James J. Vredenburgh, Beth Overmoyer, et al.. (2000). Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplantation. 26(2). 141–145. 36 indexed citations

14.

Hecht, J. Randolph, Tony Lembo, & Linnea Chap. (1997). Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. Cancer. 79(9). 1698–1702. 14 indexed citations

15.

Chap, Linnea, et al.. (1997). Miliary Osteosarcomatosis with Associated Hypocalcemia. American Journal of Clinical Oncology. 20(5). 505–508. 5 indexed citations

16.

Chap, Linnea, Robert Shpiner, Michael S. Levine, et al.. (1997). Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplantation. 20(12). 1063–1067. 33 indexed citations

17.

Bagga, Dilprit, et al.. (1997). Dietary Modulation of Omega-3/Omega-6 Polyunsaturated Fatty Acid Ratios in Patients With Breast Cancer. JNCI Journal of the National Cancer Institute. 89(15). 1123–1131. 80 indexed citations

18.

Chap, Linnea & Stephen D. Nimer. (1994). Chronic Myelogenous Leukemia Following Repeated Radiation Therapy for Histiocytosis X. Leukemia & lymphoma. 12(3-4). 315–316. 7 indexed citations

19.

Mirra, Joseph M., et al.. (1994). Case report 827. Skeletal Radiology. 23(2). 143–147. 5 indexed citations

20.

Rigolin, Vera H. & Linnea Chap. (1991). Extreme hyperkalemia induced by drugs. Postgraduate Medicine. 90(5). 129–131. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact